Bolt stock: Q3 loss narrows as Prana pipeline takes focus
Published on 11/19/2026 at 01:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline milestones move into view
- Prana Therapies' pipeline is now Bolt's primary development focus after the October transaction.
- PRA-216 is advancing in Phase 2 studies for asthma, atopic dermatitis and chronic obstructive pulmonary disease.
- The company expects proof-of-concept data across four studies from the second quarter of 2027.
Bolt Biotherapeutics reported a third-quarter net loss of USD 4.422 million for the period ended September 30, 2026, in a November 12 company release. The loss narrowed from USD 7.144 million a year earlier, while collaboration revenue fell to zero from USD 2.169 million.
Financial results reset the focus
Research and development expenses declined to USD 2.209 million from USD 6.535 million, while general and administrative expenses fell to USD 2.521 million from USD 3.337 million. The company attributed the lower research spending to a research and development tax incentive, restructuring-related savings and reduced activity. The operating loss was USD 4.730 million, compared with USD 7.703 million in the prior-year quarter.
Prana pipeline becomes central
Bolt completed its stock-for-stock reverse merger with Prana Therapies on October 23 and closed a concurrent private placement that produced approximately USD 120 million in gross proceeds. Prana's pipeline is now the company's primary development focus, led by PRA-216, a half-life-extended IL-4Ralpha/TSLP bispecific antibody.
PRA-216 is in Phase 2 development for asthma, atopic dermatitis and chronic obstructive pulmonary disease. A fourth study in eosinophilic esophagitis is planned, with proof-of-concept data across the four studies expected from the second quarter of 2027. Bolt also expects a second wholly owned INSPIRE program to enter clinical development and generate initial data in the second half of 2027.
Cash runway supports milestones
Bolt said the financing is expected to fund operations into 2028 and support multiple clinical and preclinical milestones. Sheila Gujrathi, Prana's co-founder and former chief executive, joined Bolt as chief strategy officer and a board member after the transaction.
Company profile
Bolt Biotherapeutics is a clinical-stage biotechnology company developing half-life-extended multispecific antibodies. Its INSPIRE platform combines complementary therapeutic mechanisms in fully IgG-based molecules, with PRA-216 as the lead program in inflammatory diseases. The company is based in Redwood City, California, and is also advancing additional INSPIRE-based programs, including BDC-4182.
Bolt Biotherapeutics at a glance
- Company: Bolt Biotherapeutics, Inc.
- ISIN: US0977022039
- Ticker: BOLT
- Exchange: Nasdaq
- Sector: Biotechnology
- Lead program: PRA-216
- Third-quarter period: Ended September 30, 2026
Bolt operates in the US market environment represented by the S&P 500.
